drugset / Trial / NCT02551172

Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD

NCT02551172

Phase 3 Unknown 270 enrolled Hanmi Pharmaceutical Company Limited
RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate the efficacy and safety after administration of HCP1105 in hyperlipidemic patients with high risk for CHD.

Timeline

Start
2014-10
Primary completion
2016-01
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Omega-3-acids ethyl esters Unknown
Subject Rosuvastatin Small molecule 20 mg

Indications